Filtered By:
Condition: Ischemic Stroke
Nutrition: Vitamins
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 1189 results found since Jan 2013.
Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia Society
ConclusionsSignificant progress has been made within the past 2 decades both in the pharmacological and non-pharmacological managements of this cardiac arrhythmia.
Source: Journal of Interventional Cardiac Electrophysiology - April 13, 2022 Category: Cardiology Source Type: research
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study
CONCLUSIONS: Dual antithrombotic therapy is associated with a substantially lower risk of clinically relevant bleeding without a statistically significant penalty in ischaemic events.PMID:35370126 | DOI:10.4244/EIJ-D-21-00703
Source: EuroIntervention - April 4, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Willem Lambertus Bor Anne Johanna Wilhelmina de Veer Renske H Olie Sem A O F Rikken Dean R P P Chan Pin Yin Jean Paul R Herrman Mathias Vrolix Martijn Meuwissen Tom Vandendriessche Carlos van Mieghem Michael Magro Naoual Bennaghmouch Rick Hermanides Tom A Source Type: research
Oral Anticoagulant Use for Patients with Atrial Fibrillation with Concomitant Anemia and/or Thrombocytopenia
Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice, which is associated with an increased risk of thromboembolism, heart failure and mortality.1 Previous studies in atrial fibrillation patients have reported that abnormal hemoglobin and platelet counts may be associated with adverse events. However, these studies that specifically examined the associations between hemoglobin and platelet levels and adverse outcomes reported conflicting data.2-5 Although warfarin effectively reduces the risk of ischemic stroke by 64% compared to placebo/control,6 and non-vitamin K antagonist oral antico...
Source: The American Journal of Medicine - April 2, 2022 Category: General Medicine Authors: Yung-Hsin Yeh, Yi-Hsin Chan, Shao-Wei Chen, Shang-Hung Chang, Chun-Li Wang, Chi-Tai Kuo, Gregory Y.H. Li, Shih-Ann Chen, Tze-Fan Chao Tags: Clinical Research Study Source Type: research
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Effect of retinoic acid on the neurovascular unit: A review
Brain Res Bull. 2022 Mar 26:S0361-9230(22)00080-6. doi: 10.1016/j.brainresbull.2022.03.011. Online ahead of print.ABSTRACTRetinoic acid is a metabolic product derived from vitamin A, acting at a nuclear level to maintain the proper transcriptional activity. Moreover, this molecule contributes to the development and maturation of the cerebral vascular system, playing a pivotal role in development and maintenance of neurovascular unit integrity. This physiological structure is comprised of glial cells, vascular cells, and neurons, ensuring the correct function of the blood-brain barrier and, at last instance, the homeostasis...
Source: Brain Research Bulletin - March 30, 2022 Category: Neurology Authors: Manuel R Pouso Elisa Cairrao Source Type: research
Comparison of the Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants with Warfarin in Atrial Fibrillation Patients with a History of Bleeding: A Systematic Review and Meta-Analysis
ConclusionsNOACs showed better efficacy and safety profile compared with warfarin in patients with AF and a history of bleeding. Randomized controlled trials are warranted to validate these findings.
Source: American Journal of Cardiovascular Drugs - March 16, 2022 Category: Cardiology Source Type: research
Time in therapeutic range of anticoagulation among patients with atrial fibrillation and cerebral amyloid angiopathy
Proc (Bayl Univ Med Cent). 2021 Dec 28;35(2):162-167. doi: 10.1080/08998280.2021.2013393. eCollection 2022.ABSTRACTAtrial fibrillation (AF) and cerebral amyloid angiopathy (CAA) present risks of ischemic stroke and intracerebral hemorrhage (ICH). Vitamin K antagonist use is associated with fluctuations in international normalized ratio (INR), which predispose to a higher bleeding risk. Patients with a diagnosis of AF and ICH while on a vitamin K antagonist were identified using the Rochester Epidemiology Project. Sixty patients were identified (mean age 81.3 years; 24 men). Thirty-three (55%) exhibited characteristics cons...
Source: Baylor University Medical Center Proceedings - March 9, 2022 Category: Universities & Medical Training Authors: Robert C Ward Jonathan Graff-Radford Shiva Ponamgi Stephen English Alayna Meskill Apurva B Challa David O Hodge Joshua P Slusser Alejandro A Rabinstein Samuel J Asirvatham David Holmes Christopher V DeSimone Source Type: research
